SDC1 and plasma cell myeloma: Given increasing evidence for roles in development and diseases, including some cancers, musculoskeletal and cardiovascular diseases, their long evolutionary history and widespread tissue expression, it is clear that syndecans continue to deserve scrutiny for several distinct reasons, not least the possibility that they can be diagnostic, prognostic or even targets (e.g. syndecan-1 in myeloma [242]) in specific diseases.